Aurobindo launches $1.6 billion bid to buy Novartis generics unit
Aurobindo Pharma is the only Indian company that has put in a bid for the assets, which includes an array of dermatology brands, production facilities and associated infrastructure, mostly in the US
Mumbai: Aurobindo Pharma Ltd has submitted an initial bid to buy Novartis AG’s dermatology generics drug business for about $1.6 billion, two people directly aware of the development said on condition of anonymity.
Hyderabad-based Aurobindo Pharma is the only Indian company that has put in a bid for the assets, which includes an array of dermatology brands, production facilities and associated infrastructure, mostly in the US, said one of the two people, both of whom declined to be named.
“Aurobindo has already put in a non-binding bid for the asset which has also drawn interest from other suitors which include private equity funds and other drug companies,” the person said. “Aurobindo is being advised by Credit Suisse on the transaction.”
The last date for placing binding bids is 15 June, said the second person cited above.
Emails sent to Aurobindo and Credit Suisse were not answered till press time.
Novartis is considering a sale of its dermatology generics drugs business under the Sandoz brand as it seeks to sell some of its less profitable businesses, Bloomberg reported in November.
If Aurobindo is successful, it will be the biggest outbound transaction by an Indian drug maker, the previous largest being Lupin Ltd’s acquisition of Gavis Pharmaceuticals Llc. and Novel Laboratories Inc. for $880 million in 2015.
The transaction, if it goes through, will be the second overseas acquisition by Aurobindo in less than two years. In January last year, it agreed to buy Portugal’s Generis Farmaceutica SA from Magnum Capital Partners for €135 million.
- Porsche IPO could value carmaker as high as $81 billion, CFO says
- Netflix earnings will test waters for tech giants after sell-off
- SoftBank’s Masayoshi Son, Saudi’s prince and a $22 billion test
- Sajjan Jindal keen to buy out stressed hydroelectric plants
- Beat the queue at airports, railway stations by being honest in paying income tax
- Banks turned wary of NBFCs months before IL&FS defaults
- HUL Q2: Rising input costs face off against healthy demand growth
- Q2 results: DMart finally set to face a reality check
- Temporary staffing: Decent employee additions, margin pressures may sustain
- Gujarat relief for Tata Power, Adani Power underlines sector’s harsh reality